Genotype by race and by NCI risk group
. | Race . | NCI risk group . | |||
---|---|---|---|---|---|
White . | Black . | Other . | Standard . | High . | |
ADRB21 -468 C>G, rs11168070 | |||||
CC | 113* | 67 | 5 | 150 | 81 |
CG and GG | 190 | 39 | 32 | 167 | 94 |
CCR5 +246 A>G, rs1799987 | |||||
AA | 90 | 33 | 17 | 106* | 34 |
AG and GG | 205 | 70 | 59 | 219 | 115 |
CONNEXIN 1019 C>T, rs1764391 | |||||
CC | 142 | 51 | 35 | 153 | 75 |
CT and TT | 155 | 51 | 42 | 170 | 78 |
GSTP1 313 A>G, rs947894 | |||||
AA and AG | 261* | 84 | 69 | 279 | 135 |
GG | 34 | 19 | 7 | 42 | 18 |
MBP codon 54, rs1800450 | |||||
AA | 4 | 2 | 0 | 3 | 3 |
AG and GG | 293 | 103 | 77 | 324 | 149 |
MDR1 exon 21 2677, rs 2032581 | |||||
GG | 103* | 39 | 39 | 121 | 60 |
Others | 201 | 65 | 42 | 203 | 105 |
MDR1 exon 26 3435, rs1045642 | |||||
CC | 72* | 32 | 29 | 78* | 55 |
CT and TT | 252 | 74 | 53 | 259 | 120 |
MTHFR 677 C>T, rs1801133 | |||||
CC | 141* | 29 | 44 | 133 | 81 |
CT and TT | 185 | 78 | 39 | 205 | 97 |
MTHFR 1298 A>C, rs1801131 | |||||
AA | 139* | 75 | 40 | 163 | 91 |
AC and CC | 187 | 32 | 43 | 175 | 87 |
NQO1 609 C>T, rs 1800566 | |||||
CC | 182* | 45 | 39 | 190 | 76 |
CT and TT | 117 | 58 | 39 | 137 | 77 |
CYBA P22, rs4673 | |||||
CC | 124 | 55 | 34 | 135* | 78 |
CT and TT | 174 | 46 | 42 | 189 | 73 |
RFC 80 A>G, rs1051266 | |||||
AA and AG | 208 | 70 | 61 | 225 | 114 |
GG | 96 | 35 | 21 | 97 | 55 |
TPMT 460 G>A, rs 1142345 | |||||
AA and AG | 19 | 10 | 3 | 23 | 9 |
GG | 284 | 95 | 75 | 308 | 146 |
TYMS - 827 promoter enhancer repeat | |||||
3AND3 | 85* | 36 | 35 | 100 | 56 |
Others | 224 | 69 | 44 | 222 | 115 |
VDR Fok1 Start site, rs1073581 | |||||
CC | 130 | 39 | 28 | 127 | 70 |
CC and CT | 175 | 65 | 49 | 205 | 84 |
VDR intron 8 G>A, rs1544410 | |||||
AA and AG | 93 | 24 | 15 | 94 | 38 |
GG | 51 | 25 | 23 | 67 | 32 |
. | Race . | NCI risk group . | |||
---|---|---|---|---|---|
White . | Black . | Other . | Standard . | High . | |
ADRB21 -468 C>G, rs11168070 | |||||
CC | 113* | 67 | 5 | 150 | 81 |
CG and GG | 190 | 39 | 32 | 167 | 94 |
CCR5 +246 A>G, rs1799987 | |||||
AA | 90 | 33 | 17 | 106* | 34 |
AG and GG | 205 | 70 | 59 | 219 | 115 |
CONNEXIN 1019 C>T, rs1764391 | |||||
CC | 142 | 51 | 35 | 153 | 75 |
CT and TT | 155 | 51 | 42 | 170 | 78 |
GSTP1 313 A>G, rs947894 | |||||
AA and AG | 261* | 84 | 69 | 279 | 135 |
GG | 34 | 19 | 7 | 42 | 18 |
MBP codon 54, rs1800450 | |||||
AA | 4 | 2 | 0 | 3 | 3 |
AG and GG | 293 | 103 | 77 | 324 | 149 |
MDR1 exon 21 2677, rs 2032581 | |||||
GG | 103* | 39 | 39 | 121 | 60 |
Others | 201 | 65 | 42 | 203 | 105 |
MDR1 exon 26 3435, rs1045642 | |||||
CC | 72* | 32 | 29 | 78* | 55 |
CT and TT | 252 | 74 | 53 | 259 | 120 |
MTHFR 677 C>T, rs1801133 | |||||
CC | 141* | 29 | 44 | 133 | 81 |
CT and TT | 185 | 78 | 39 | 205 | 97 |
MTHFR 1298 A>C, rs1801131 | |||||
AA | 139* | 75 | 40 | 163 | 91 |
AC and CC | 187 | 32 | 43 | 175 | 87 |
NQO1 609 C>T, rs 1800566 | |||||
CC | 182* | 45 | 39 | 190 | 76 |
CT and TT | 117 | 58 | 39 | 137 | 77 |
CYBA P22, rs4673 | |||||
CC | 124 | 55 | 34 | 135* | 78 |
CT and TT | 174 | 46 | 42 | 189 | 73 |
RFC 80 A>G, rs1051266 | |||||
AA and AG | 208 | 70 | 61 | 225 | 114 |
GG | 96 | 35 | 21 | 97 | 55 |
TPMT 460 G>A, rs 1142345 | |||||
AA and AG | 19 | 10 | 3 | 23 | 9 |
GG | 284 | 95 | 75 | 308 | 146 |
TYMS - 827 promoter enhancer repeat | |||||
3AND3 | 85* | 36 | 35 | 100 | 56 |
Others | 224 | 69 | 44 | 222 | 115 |
VDR Fok1 Start site, rs1073581 | |||||
CC | 130 | 39 | 28 | 127 | 70 |
CC and CT | 175 | 65 | 49 | 205 | 84 |
VDR intron 8 G>A, rs1544410 | |||||
AA and AG | 93 | 24 | 15 | 94 | 38 |
GG | 51 | 25 | 23 | 67 | 32 |
Significantly different frequency of genotypic groups by race or by NCI risk group.